miRNA 371 for Testicular Cancer

Not currently recruiting at 456 trial locations

Overseen By Patricia O'Kane

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: SWOG Cancer Research Network

Disqualifiers: Other cancers, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether a blood marker called miRNA 371 can predict cancer recurrence in individuals with germ cell tumors. By collecting and analyzing blood samples, researchers aim to determine if this marker can indicate the likelihood of cancer returning. Participants will provide blood samples every 3-6 months for up to three years. This trial suits those recently diagnosed with a germ cell tumor, who have not yet begun treatment, and are willing to participate in regular blood sample collections. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could enhance future cancer monitoring.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores the potential of miRNA 371 as a novel biomarker for germ cell tumors. Unlike traditional treatments that focus on surgery, chemotherapy, or radiation, this approach involves collecting blood samples to detect miRNA 371 levels, which could offer a non-invasive way to monitor the disease. This method could lead to earlier detection and more precise tracking of tumor activity without the need for more invasive procedures. If successful, it could revolutionize how germ cell tumors are monitored and managed, making the process easier and potentially more accurate for patients.

Who Is on the Research Team?

Craig R Nichols

Principal Investigator

SWOG Cancer Research Network

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients must have a new diagnosis of a germ cell tumor. confirmed pathologically or serologically (diagnostic elevation of human chorionic gonadotropin [HCG]/alpha-fetoprotein [AFP]). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible

If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration

Patients must be registered within 42 days after diagnosis and prior to initiation of a management plan or treatment for the disease

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Patients undergo collection of blood every 3-6 months to assess miRNA 371 for outcome prediction

Up to 3 years

Blood collection every 3-6 months

Follow-up

Participants are monitored for safety and effectiveness after observational period

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Blood Product Collection

How Is the Trial Designed?

Group I: Observational (blood collection) Experimental Treatment 2 Interventions

Patients undergo collection of blood every 3-6 months for up to 3 years.

Who Is Running the Clinical Trial?

SWOG Cancer Research Network

Lead Sponsor

Trials

403

Recruited

267,000+

Southwest Oncology Group

Lead Sponsor

Trials

389

Recruited

260,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+